Abstract
Hidradenitis suppurativa (HS, acne inversa) is a chronic and recurrent disease affecting the apocrine-bearing areas of skin. Although previously thought to arise from inflammation of the apocrine glands, evidence now points to follicular occlusion as the primary event, though the disease has distinct differences from acne vulgaris where occlusion also plays a role. Hidradenitis suppurativa varies in severity, ranging from occasional isolated inflammatory nodules to numerous painful inflammatory nodules with draining ulcers, sinus tracts, and scarring. While there is no cure for hidradenitis suppurativa, nor a standard protocol for treatment, therapy can help control the disease. Treatment options including oral antibiotics, hormonal therapy, immunosuppressants, biologics, and surgery are reviewed. In addition to medical and surgical therapy, supporting the psychosocial well-being of HS patients, especially adolescents, is very important, and HS support groups or referral for psychological evaluation can be helpful.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- FDA:
-
Food and Drug Administration
- HS:
-
Hidradenitis suppurativa
- Kg:
-
Kilogram
- Mg:
-
Milligram
- Nd:YAG:
-
Neodymium:yttrium-aluminum-garnet
- PUVA:
-
Psoralen plus ultraviolet A
References
Mengesha YM, Holcombe TC, Hansen RC. Prepubertal hidradenitis suppurativa: two case reports and review of the literature. Pediatr Dermatol. 1999;16(4):292–6.
Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother. 2004;5:1767–70.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case–control studies. J Am Acad Dermatol. 2008;59:596–601.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitits suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.
Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729–39.
Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa – characteristics and consequences. Clin Exp Dermatol. 1996;21:419–23.
Von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144:809–13.
Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328–32.
Clemmensen OJ. Topical treatment of hidradenitits suppurativa with clindamycin. Int J Dermatol. 1983;22:325–8.
Jemec GB, Faber M, Gutschik E, et al. The bacteriology of hidradenitis suppurativa. Dermatology. 1996;193:203–6.
Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol. 1999;140:90–5.
Sartorius K, Killasli H, Oprica C, et al. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166:879–83.
Shaughnessy DM, Greminger RR, Margolis IB, et al. Hidradenitis suppurativa. A plea for early operative treatment. JAMA. 1972;222:320–1.
Jemec GB, Wendelbow P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–4.
Mendonça CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154:977–8.
Van der Zee HH, Boer J, Prens EP, et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143–7.
Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219:148–54.
Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011;222:49–58.
Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. 2006;17:211–3.
Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222:342–6.
Jones DH, Cunliffe WJ, King K. Hidradenitis suppurativa—lack of success with 13-cis-retinoic acid. Br J Dermatol. 1982;107:252.
Dicken CH, Powell ST, Spear KL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1984;11:500–2.
Norris JFB, Cunliffe WJ. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol. 1986;11:579–83.
Brown CF, Gallup DG, Brown VM. Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol. 1988;158:12–5.
Boer J, van Gemert M. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73–6.
Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology. 2009;218:134–5.
Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170–5.
Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre-and postmenopausal women with hidradenitis suppurativa. Br J Dermatol. 1996;134:1057–9.
Joseph MA, Jayaseelan E, Ganapathi B, et al. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat. 2005;16:75–8.
Mortimer PS, Dawber RP, Gales MA, et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263–8.
Sawers RS, Randall VA, Ebline FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115:269–74.
Roase RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral cyclosporine. Clin Exp Dermatol. 2006;31:154–6.
Buckley DA, Rogers S. Cyclosprin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289P–90.
Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27:523–9.
Van der Zee HH, Prens EP. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology. 2011;223:169–73.
Van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–8.
Adams DR, Gordon KB, Devenyi AG, et al. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540–2.
Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726–9.
Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046–9.
Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343–5.
Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46: 1287–91.
Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41–4.
Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;154:1105–7.
Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumor necrosis factor-α blockers the ultimate alternative? Br J Dermatol. 2008;159:761–3.
Lasocki A, Sinclair R, Foley P, et al. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol. 2010;51:186–90.
Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158:370–4.
Delage M, Samimi M, Atlan M, et al. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol. 2011;91:169–71.
Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624–8.
Usmani N, Clayton TH, Everett S, et al. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204–5.
Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–17.
Sotiriou E, Apalla Z, Ioannidos D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol. 2009;89:82–3.
Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567–72.
Pelekanou A, Kanni T, Savva A, et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol. 2010;19:538–40.
Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60:565–73.
Zangrilli A, Esposito M, Mio G, et al. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2008;22:1260–2.
Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–4.
Moul DK, Korman N. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142:1110–1.
Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580–4.
Sotiriou E, Apalla Z, Vakirilis E, et al. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2009;19:180–1.
Amando M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49: 950–5.
Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49:1445–9.
Sotiriou E, Goussi C, Lallas A, et al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. 2012;11(Suppl):15–20.
Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391–8.
Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26(7):911–4.
Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92:320–1.
Bong JL, Shalders K, Saihan E. Treatment of persistent painful nodules of hidradenitis suppurativa with cryotherapy. Clin Exp Dermatol. 2003;28:241–4.
Guglielmetti A, Bedoya J, Acuna M, et al. Successful aminolevulinic acid photodynamic therapy for recalcitrant severe hidradenitis suppurativa. Photodermatol Photoimmunol Photomed. 2010;26:110–1.
Saraceno R, Teoli M, Casciello C, et al. Methyl aminolaevulinate photodynamic therapy for the treatment of hidradenitis suppurativa and pilonidal cysts. Photodermatol Photoimmunol Photomed. 2009;25: 164–5.
Schweiger ES, Riddle CC, Aires DJ. Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. J Drugs Dermatol. 2011;10:381–6.
Gold M, Bridges TM, Bradshaw VL, et al. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol. 2004;3:S32–5.
Sotiriou E, Apalla Z, Maliamani F, et al. Treatment of recalcitrant hidradenitis suppurativa with photodynamic therapy: report of five cases. Clin Exp Dermatol. 2009;34:e235–6.
Strauss RM, Pollock B, Stables GI, et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol. 2005;152:803–4.
Shareef M, Dawe R. Bath psoralen plus ultraviolet A for hidradenitis suppurativa: a review of 13 patients. Br J Dermatol. 2011;164:895–6.
O’Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg. 2005;116:1575–6.
Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br J Dermatol. 1994;131:551–6.
Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol. 1996;34:465–9.
Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol. 2002;47:280–5.
Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36:208–13.
Madan V, Hindle E, Hussain W, et al. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol. 2008;159:1309–14.
Mahmoud BH, Tierney E, Hexsel C, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010;62:637–45.
Ritz JP, Runkel N, Haier J, et al. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998;13:164–8.
Van Hattem S, Spoo JR, Horvath B, et al. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg. 2012;38:494–7.
Van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63:475–80.
Bohn J, Svensson H. Surgical treatment of hidradenitis suppurativa. Scand J Plast Reconstr Surg Hand Surg. 2001;35:305–9.
Bieniek A, Matusiak L, Okulewicz-Gojlik D, et al. Surgical treatment of hidradenitis suppurativa: experiences and recommendations. Dermatol Surg. 2010;36:1998–2004.
Buyukasik O, Hasdemir AO, Kahramansoy N, et al. Surgical approach to extensive hidradenitis suppurativa. Dermatol Surg. 2011;37:835–42.
Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg. 2000;26:638–43.
Watson JD. Hidradenitis suppurativa – a clinical review. Br J Plast Surg. 1985;38:567–9.
Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppurativa: a study of 106 cases. Surgeon. 2005;3:23–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Jen, M., Chang, M.W. (2014). Hidradenitis Suppurativa. In: Tom, W. (eds) Severe Skin Diseases in Children. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39532-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-39532-1_4
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-39531-4
Online ISBN: 978-3-642-39532-1
eBook Packages: MedicineMedicine (R0)